DK0986393T3 - Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer - Google Patents

Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer

Info

Publication number
DK0986393T3
DK0986393T3 DK98923772T DK98923772T DK0986393T3 DK 0986393 T3 DK0986393 T3 DK 0986393T3 DK 98923772 T DK98923772 T DK 98923772T DK 98923772 T DK98923772 T DK 98923772T DK 0986393 T3 DK0986393 T3 DK 0986393T3
Authority
DK
Denmark
Prior art keywords
cancer
nitroxide
prodrug
prophylactic
therapeutic treatment
Prior art date
Application number
DK98923772T
Other languages
Danish (da)
English (en)
Inventor
James B Mitchell
Angelo Russo
Anne Marie Deluca
Murali Krishna Cherukuri
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK0986393T3 publication Critical patent/DK0986393T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
DK98923772T 1997-05-27 1998-05-27 Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer DK0986393T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4772497P 1997-05-27 1997-05-27
PCT/US1998/010685 WO1998053835A1 (en) 1997-05-27 1998-05-27 The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer

Publications (1)

Publication Number Publication Date
DK0986393T3 true DK0986393T3 (da) 2004-07-05

Family

ID=21950574

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98923772T DK0986393T3 (da) 1997-05-27 1998-05-27 Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer

Country Status (10)

Country Link
EP (1) EP0986393B1 (https=)
JP (3) JP4856294B2 (https=)
AT (1) ATE262330T1 (https=)
AU (1) AU746505B2 (https=)
CA (1) CA2289017C (https=)
DE (1) DE69822626T8 (https=)
DK (1) DK0986393T3 (https=)
ES (1) ES2216286T3 (https=)
PT (1) PT986393E (https=)
WO (1) WO1998053835A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
EP1089734A2 (en) * 1998-06-26 2001-04-11 Georgetown University Medical Center Use of tempo and tempo derivatives for inducing cell death
US20040219201A1 (en) * 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
EP1633337A4 (en) * 2003-05-29 2007-09-05 Mitos Pharmaceuticals Inc METHODS OF USING NITROXIDES IN CONJUNCTION WITH PHOTOSENSITIZERS AND SENOSENSITIZERS
US20120046314A1 (en) * 2005-02-02 2012-02-23 Mitos, Inc. Nitroxides for use in treating or preventing neoplastic disease
US8466130B2 (en) 2009-09-04 2013-06-18 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
EP2139522A2 (en) * 2007-03-06 2010-01-06 Colby Pharmaceutical Company Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers
US8853277B2 (en) 2009-11-30 2014-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
US20180078539A1 (en) 2016-03-23 2018-03-22 Louis Habash T-cell regulation in t-cell mediated diseases by reducing pathogenic function of th17 in a human subject through treatment with a nitroxide
US10231959B2 (en) 2016-03-23 2019-03-19 Louis Habash Increasing expression level of apoptosis-related genes by treating a human subject with a nitroxide
JP2019509352A (ja) * 2016-03-23 2019-04-04 ルイス ハバシュ, ヒトの被験物質をニトロキシドで処理することによってapoptosis関連遺伝子の発現レベルを増加させる

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758580A (en) * 1985-06-26 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Inhibiting growth of tumors with certain substituted phenoxy dimethyl alkanoic acids, esters or salts
ATE113469T1 (de) * 1990-06-21 1994-11-15 Edith Dr Huland Verwendung zytokinhaltiger aerosole und zytokinhaltige aerosole selbst.
US6605619B1 (en) * 1992-03-20 2003-08-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxides as protectors against oxidatives stress
JPH11500119A (ja) * 1995-02-16 1999-01-06 エフ・ホフマン−ラ ロシュ アーゲー インターロイキン12を用いる脈管形成の阻害

Also Published As

Publication number Publication date
WO1998053835A1 (en) 1998-12-03
JP2013121964A (ja) 2013-06-20
DE69822626T8 (de) 2005-02-03
EP0986393B1 (en) 2004-03-24
CA2289017C (en) 2008-07-22
AU746505B2 (en) 2002-05-02
EP0986393A1 (en) 2000-03-22
DE69822626T2 (de) 2004-08-12
JP2002500671A (ja) 2002-01-08
CA2289017A1 (en) 1998-12-03
ES2216286T3 (es) 2004-10-16
JP4856294B2 (ja) 2012-01-18
AU7598798A (en) 1998-12-30
DE69822626D1 (de) 2004-04-29
ATE262330T1 (de) 2004-04-15
PT986393E (pt) 2004-06-30
JP2009185034A (ja) 2009-08-20
JP5270413B2 (ja) 2013-08-21

Similar Documents

Publication Publication Date Title
DK0858330T3 (da) Præparater indeholdende derivater af hydroperoxyeicosatetraensyre og fremgangsmåder til anvendelse ved behandling af sygdom
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
TR199900827T2 (xx) Siklooksigenaz-2 inhibit�rlerinin neoplazinin tedavisinde ve �nlenmesinde kullan�m�.
NO943877L (no) Hemming av proliferasjon av glatte muskelceller og restenose
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
DE69717148D1 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
DK0735868T3 (da) Anvendelse af ikke-steroide cyclooxygenaseinhibitorer til fremstilling af et medikament til behandling af forhøjet intrakul
DK0664708T3 (da) Metode til behandling af cancer ved kombinationsbehandling med 2'-halogenmethylidenderivater og et S-fase- eller M-fase-spe
BR9811099A (pt) Inibidores de urocinase
DK0804437T3 (da) [a]-Annelerede pyrrolderivater og deres anvendelse i farmacien
MY119375A (en) Treatment of tinnitus using neuroprotective agents
DE69825154D1 (de) Pyridazinone als inhibitoren von cyclooxygenase-2
UA41355C2 (uk) Засіб для лікування нейро-сніду
DE60039730D1 (de) Genetisch manipulierte Herpesviren zur Behandlung von Tumoren
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
GB0130677D0 (en) Medicaments and novel compounds
TR199900951T2 (xx) G���s kanserinin engellenmesi i�in y�ntemler.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
BR0311223A (pt) Método para o uso de derivados de piranindol para tratar infecção pelo vìrus da hepatite c
TR200003194T2 (tr) Hastalık tedavisine mahsus sPLA2 önleyici bileşikler
NO923198L (no) Terapeutiske midler
ATE320797T1 (de) Verwendung von 6-dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz